Benefits
May ease perceived stress at a 30 mg dose
In a four-week placebo-controlled trial in 60 adults with self-reported stress, the stress score on a standard questionnaire ended about 2.6 points lower on Ashwa.30 than on placebo, a moderate effect that only just reached significance. When the analysis was limited to participants who followed the protocol, the gap narrowed and was no longer statistically reliable.
Helps temper the cortisol response to a stress test
In the four-week stress trial, salivary cortisol rose after a cold-pressor stress test at day 28 in the placebo group but stayed fairly flat on Ashwa.30. At day 7 the groups did not differ. The maker promotes a nearly 40 percent cortisol drop within a week, but that figure comes from a separate study we could not find in the peer-reviewed literature.
Supports aerobic endurance in active adults
In an eight-week trial of mostly male adults who already exercised most days, estimated VO2max rose about 10 percent on Ashwa.30 versus about 1 percent on placebo, with lower blood lactate at a hard treadmill stage. That VO2max figure was calculated from peak versus resting heart rate rather than measured, so it largely tracks a higher peak heart rate on the retest; only completers were analyzed and the result has not been repeated.
What the eightfold endurance figure really means
Marketing describes an eightfold improvement in endurance. That number is the ratio between the two groups' percentage changes in estimated VO2max, roughly 10 percent against 1 percent. The estimate rose about 2.9 mL/kg/min on Ashwa.30 against 0.35 on placebo over eight weeks, worthwhile if it holds up, but nothing a user would experience as eight times anything.
Anti-fatigue claim not borne out by the published data
In the four-week stress trial, fatigue scores at day 28 did not differ between groups and were numerically lower on placebo, and anxiety and depression scores did not separate from placebo either. In the eight-week endurance trial, post-exercise fatigue ratings also did not differ from placebo; perceived exertion fell slightly more than on placebo, by about a third of a point on a 6 to 20 scale.
Borrows from wider ashwagandha stress research at higher doses
Pooled analyses of other ashwagandha extracts report lower stress scores and lower cortisol, mostly at 250 to 600 mg a day, and a separate pooled analysis favored ashwagandha for physical performance. Certainty for stress was rated low, one analysis found perceived stress did not change, and none of that work tested Ashwa.30.
Mechanism of action
Withanolides and the stress hormone axis
Withanolides are the steroidal lactones used to standardize ashwagandha. Across trials of other root extracts, ashwagandha lowered cortisol, which points to an action on the hypothalamic-pituitary-adrenal axis. At 30 mg, Ashwa.30 supplies at least about 4.5 mg of withanolides a day.
The ATP-active fraction is a company concept
The second marker is a withanolide-free fraction the maker calls ATP-active, measured by weight and described as rich in arabinogalactan polysaccharides, saponins and minor constituents. The idea that it drives cellular energy rests on company preclinical work and a company-authored summary, not independent study.
Lactate and muscle-stress markers during exercise
In the endurance trial, blood lactate at a hard treadmill stage was lower and creatine phosphokinase fell about 16 percent on Ashwa.30 against 7 percent on placebo. The investigators read this as longer reliance on aerobic metabolism and less muscle energy stress; these are marker changes from one trial, not a proven mechanism.
Low dose by proprietary design
Natural Remedies says its proprietary Bioactive Optimization Technology isolates the most effective parts of the plant so that 30 mg can stand in for hundreds. The published methods describe only an ethanol and water root extraction, so the premise that this process beats ordinary extracts cannot be checked independently.
Clinical trials
28-day randomized, double-blind, placebo-controlled trial of Ashwa.30 30 mg/day, funded by Natural Remedies, with five of the seven authors employed by the company (Lopresti AL, Smith SJ, Bethapudi B, R AA, Mundkinajeddu D, D'Souza P, Lakshmikanthan S 2026, Adv Ther, published online August 2026, PMID 42593642).
60 adults aged 18 to 65 with mild to severe self-reported stress in Perth, Australia, predominantly women; 59 completed.
Adjusted day-28 stress scores were 10.47 on Ashwa.30 and 13.06 on placebo, a 2.60 point difference (95% CI 0.04 to 5.15, p=0.046) in the full analysis set; the per-protocol difference of 2.04 points was not statistically significant (p=0.116). Both groups improved, with stress falling 46.2% on Ashwa.30 and 32.9% on placebo, so a headline percentage drop on Ashwa.30 alone overstates the difference from placebo. Anxiety, depression and fatigue scores did not differ between groups. Salivary cortisol after the cold-pressor test stayed flatter on Ashwa.30 at day 28 (p=0.047) but not at day 7. The authors describe it as a preliminary signal-detection study.
Eight-week randomized, double-blind, placebo-controlled trial with 2:1 allocation, funded and supplied by Natural Remedies and run with a contract research organization in India (Prajapati H, Satia M, Shah D, Basera I, Shah T 2026, Phytother Res 40(8):4978-4987, PMID 41846233).
66 healthy, mostly male adults (59 of 66) aged 18 to 45 who had exercised almost five days a week for two years (44 Ashwa.30, 22 placebo); 63 completed and only completers were analyzed.
Estimated VO2max rose 10.11% on Ashwa.30 (29.29 to 32.20 mL/kg/min) versus 1.23% on placebo, a significant between-group difference. VO2max was not measured but calculated as 15 times peak divided by resting heart rate, so the gain mirrors a rise in peak heart rate from about 163 to 177 beats per minute as more participants reached the treadmill's eighth stage. Stage 6 lactate was lower; post-exercise fatigue ratings did not differ from placebo. No treatment-related adverse events; not independently replicated.
Systematic review and meta-analysis of randomized trials of ashwagandha extracts (Akhgarjand C, Asoudeh F, Bagheri A, Kalantar Z, Vahabi Z, Shab-Bidar S, Rezvani H, Djafarian K 2022, Phytother Res 36(11):4115-4124, PMID 36017529). Class evidence: it did not test Ashwa.30.
12 trials with 1,002 participants aged roughly 25 to 48.
Ashwagandha reduced anxiety and stress scores compared with placebo, and the dose-response analysis favored stress benefits at 300 to 600 mg a day, ten to twenty times the Ashwa.30 dose. Heterogeneity was high and the reviewers rated the certainty of the evidence as low for both outcomes.
Systematic review and meta-analysis restricted to trials of at least two weeks using 250 mg a day or more (Albalawi AA 2025, Nutr Health 31(4):1395-1408, PMID 40746175). Class evidence: it did not test Ashwa.30.
488 participants across seven cortisol trials and six perceived-stress trials.
Cortisol fell by 1.16 µg/dL on average (95% CI -1.64 to -0.69), but perceived stress scores did not differ from placebo (SMD -0.355, p=0.40). That split between a hormone marker and how people feel is directly relevant here, because Ashwa.30's clearest stress findings are also a cortisol pattern plus a borderline questionnaire result.